Morgan flags SUS GLP-1 cost-access dilemma; limited stock impact

Morgan Stanley analysts note Brazil's public health system (SUS) faces a trade-off between the high cost of GLP-1 obesity drugs and the need to expand access, which could limit near-term adoption. The assessment suggests a constrained rollout, with uncertain fiscal and market implications for drugmakers. The report is an analyst view, not a policy change, so the impact on related equities appears muted.